VG Life Sciences Inc. (VGLS) Stock Analysis
DELISTED 2026
What happened to VG Life Sciences Inc. (VGLS) stock?
VG Life Sciences Inc. (VGLS) no longer trades on public markets. It was delisted in July 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
VG Life Sciences Inc. (VGLS) trades at $0.2202. VG Life Sciences Inc. is a biotechnology company focused on developing transformative therapies for cancer, infectious diseases, and autoimmune diseases. Their pipeline includes solutions targeting chronic inflammation and drug-resistant cancers. Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for VGLS: VGLS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VGLS against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
VGLS: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →VG Life Sciences Inc. (VGLS) Healthcare & Pipeline Overview
VG Life Sciences Inc., a biotechnology company founded in 1995, focuses on researching and developing therapies for cancer, infectious diseases, and autoimmune disorders by targeting chronic inflammation and drug resistance. Their pipeline includes VG1177, metabolic disruption technology (MDT), and targeted peptide technology (TPT).
What Is the Investment Thesis for VGLS?
VG Life Sciences Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on innovative therapies targeting chronic inflammation, cancer, and autoimmune diseases addresses significant unmet medical needs. However, with a market capitalization of $0.00B and a small team of one employee, the company faces substantial challenges in funding, research and development, and regulatory approvals. The negative P/E ratio of -3.15 reflects the company's current lack of profitability. Potential catalysts include advancements in its VG1177, MDT, and TPT programs. The company's success hinges on securing funding, achieving positive clinical trial outcomes, and navigating the complex regulatory landscape. The extremely negative beta of -72.29 suggests an inverse correlation with the market, but should be interpreted cautiously given the company's size and OTC status.
Based on FMP financials and quantitative analysis
VGLS Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited resources.
- P/E ratio of -3.15 reflects the company's current lack of profitability.
- Operates with only 1 employee, highlighting its early-stage nature and reliance on external partnerships.
- Focus on innovative therapies targeting chronic inflammation, cancer, and autoimmune diseases addresses significant unmet medical needs.
- Trades on the OTC market, indicating higher risk and lower liquidity compared to major exchanges.
Who Are VGLS's Competitors?
VGLS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADXS Ayala Pharmaceuticals, Inc. | $0.60 | +0.00% | $25.7M | 43 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VGLS's Key Strengths?
Proprietary technology platforms (VG1177, MDT, TPT).
- Focus on addressing unmet medical needs.
- Potential for first-mover advantage in specific therapeutic areas.
- Operates as a subsidiary of Feelux Co., Ltd.
What Are VGLS's Weaknesses?
Limited financial resources (market cap of $0.00B).
- Small team (1 employee).
- Early-stage development of therapies.
- Reliance on external partnerships for commercialization.
What Could Drive VGLS Stock Higher?
Clinical trial results for VG1177 in treating chronic inflammation.
- Preclinical data release for MDT compounds in drug-resistant cancers.
- Announcement of strategic partnerships or collaborations.
- Continued research and development of TPT for autoimmune and infectious diseases.
- Efforts to secure additional funding for research and development.
What Are the Key Risks for VGLS?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to secure funding for research and development.
- Unsuccessful clinical trial outcomes.
- Regulatory hurdles and lengthy approval processes.
- Competition from larger pharmaceutical and biotechnology companies.
- Limited financial resources and small team size.
What Are the Growth Opportunities for VGLS?
- Advancement of VG1177: VG Life Sciences' VG1177 targets chronic inflammation by eliminating CLIP. The market for anti-inflammatory therapies is substantial, driven by the prevalence of autoimmune diseases and chronic conditions. Successful clinical trials and regulatory approval could lead to significant revenue generation. The timeline for commercialization depends on clinical trial progress, with potential market entry within 3-5 years pending positive results.
- Development of Metabolic Disruption Technology (MDT): MDT compounds disrupt tumor cell metabolism, sensitizing cancer cells to treatment. The oncology market is a multi-billion dollar industry, with a growing demand for therapies that overcome drug resistance. Positive preclinical and clinical data could attract partnerships with larger pharmaceutical companies. Commercialization is contingent on successful clinical trials, potentially within 5-7 years.
- Expansion of Targeted Peptide Technology (TPT): TPT aims to eliminate pro-inflammatory immune cells, offering a potential treatment for autoimmune and infectious diseases. The market for autoimmune disease therapies is expanding, driven by an aging population and increased diagnosis rates. Successful development and commercialization of TPT could generate significant revenue streams. The timeline for market entry depends on clinical trial outcomes, potentially within 4-6 years.
- Strategic Partnerships and Collaborations: VG Life Sciences can pursue strategic partnerships with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its therapies. Collaborations can provide access to funding, expertise, and resources, increasing the likelihood of success. The timing of partnerships is uncertain but could occur at any stage of development.
- Expansion into New Therapeutic Areas: VG Life Sciences can leverage its expertise in peptide technology and metabolic disruption to expand into new therapeutic areas, such as neurodegenerative diseases or cardiovascular diseases. This diversification could reduce risk and increase long-term growth potential. The timeline for expansion depends on the company's research and development efforts, potentially within 5-10 years.
What Are VGLS's Competitive Advantages?
- Proprietary technology platforms (VG1177, MDT, TPT) provide a competitive advantage.
- Patents protect its innovative therapies from direct competition.
- Focus on addressing unmet medical needs in challenging disease areas.
- Potential for first-mover advantage in specific therapeutic areas.
What Does VGLS Do?
Founded in 1995, VG Life Sciences Inc. (VGLS) is a biotechnology company dedicated to researching and developing innovative therapies for challenging diseases, including cancer, infectious diseases, and autoimmune disorders. The company's core focus lies in addressing chronic inflammation and drug resistance, aiming to provide transformative solutions where current treatments fall short. VGLS's lead product, VG1177, employs a synthesized peptide designed to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) displayed on specific B cells, which contribute to chronic inflammation. In addition to VG1177, VG Life Sciences is developing metabolic disruption technology (MDT) compounds that disrupt tumor cell metabolism, making them more susceptible to treatment. Hydroxychloroquine, an MDT compound, is being explored in combination with other cancer drugs to combat drug-resistant cancers. The company's targeted peptide technology (TPT) aims to eliminate pro-inflammatory immune cells, offering a potential treatment for autoimmune and infectious diseases. Formerly known as Viral Genetics Inc., VG Life Sciences Inc. changed its name in November 2012. The company operates as a subsidiary of Feelux Co., Ltd. and is based in Santa Barbara, California.
What Products and Services Does VGLS Offer?
- Researches and develops therapies for cancer.
- Develops treatments for infectious diseases.
- Creates solutions for autoimmune diseases.
- Targets chronic inflammation with innovative therapies.
- Develops metabolic disruption technology (MDT) to combat drug-resistant cancers.
- Utilizes targeted peptide technology (TPT) to eliminate pro-inflammatory immune cells.
How Does VGLS Make Money?
- Develops and patents novel therapeutic technologies.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
- Potentially manufactures and sells therapies directly, pending regulatory approvals and market demand.
What Industry Does VGLS Operate In?
VG Life Sciences Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The industry is driven by innovation and the pursuit of novel therapies for unmet medical needs. Market trends include the increasing focus on personalized medicine, immunotherapy, and gene therapy. VG Life Sciences competes with both large pharmaceutical companies and smaller biotechnology firms, including AAGH, ADXS, AGNPF, AGTX, and APLIF, all of whom are vying for market share in the development of innovative therapies.
Who Are VGLS's Key Customers?
- Pharmaceutical companies seeking innovative therapies to license or acquire.
- Patients suffering from cancer, infectious diseases, and autoimmune disorders.
- Healthcare providers looking for effective treatments for their patients.
- Research institutions interested in collaborating on the development of new therapies.
Company Profile
VG Life Sciences Inc. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in New York, US. The company is led by CEO William Farrand. VGLS has traded publicly since 1999.
Key Financial Metrics
Return on equity for VG Life Sciences Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -152.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
VG Life Sciences Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
VGLS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future direction, indicating that those closest to the business see potential upside.
- Community sentiment has shifted positively, driven by recent announcements regarding product developments and partnerships.
- Market perception has been bolstered by increased media coverage highlighting the company's innovative approaches in the life sciences sector.
- Analysts are noting a growing interest in the biotech space, with VG Life Sciences positioned as a potential player in emerging markets.
Bear Case
- Despite recent insider buying, overall trading volume remains low, which could indicate a lack of broader market interest.
- Community sentiment is mixed, with some investors expressing concerns about the company's ability to translate research into viable products.
- The competitive landscape in biotech is fierce, and VG Life Sciences faces challenges from established players with more resources.
- Recent regulatory hurdles in the life sciences industry could pose risks to the company's timeline and growth prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VGLS Latest News
No recent news available for VGLS.
Leadership: William Farrand
CEO
William Farrand serves as the CEO of VG Life Sciences Inc. Information regarding his detailed background, including career history, education, and previous roles, is not available in the provided data. Therefore, a comprehensive biography cannot be constructed at this time. Further research would be required to provide a more detailed profile.
Track Record: Due to the limited information available, it is not possible to assess William Farrand's track record at VG Life Sciences Inc. Key achievements, strategic decisions, and company milestones under his leadership are currently unknown. Additional data is needed to evaluate his performance and contributions to the company.
VGLS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet minimum financial standards or have chosen not to provide regular disclosures. Companies in this tier may be newly formed, distressed, or have limited operating history. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, OTC Other stocks often lack stringent listing requirements, resulting in increased risk and potential for speculative trading.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in VGLS.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- The OTC Other tier designation indicates a higher risk of fraud or mismanagement.
- The company's small size and limited resources increase the risk of business failure.
- Dependence on external funding sources makes the company vulnerable to market conditions.
- Verify the company's legal standing and registration.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and market potential.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- The company has been in operation since 1995.
- VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.
- Focuses on developing therapies for significant unmet medical needs.
Common Questions About VGLS (Healthcare)
What happened to VG Life Sciences Inc. (VGLS) stock?
VG Life Sciences Inc. (VGLS) no longer trades on public markets. It was delisted in July 2026. The figures below are historical and are not a current quote.
Can I still buy VGLS shares?
No. VGLS stopped trading on public markets in July 2026, so the shares are not available through a broker. Anything you see quoted for VGLS elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before VGLS stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to VG Life Sciences Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does VG Life Sciences Inc. do?
VG Life Sciences Inc. is a biotechnology company focused on researching and developing innovative therapies for cancer, infectious diseases, and autoimmune disorders. Their core focus lies in addressing chronic inflammation and drug resistance.
What do analysts say about VGLS stock?
As of March 18, 2026, there is no available analyst coverage for VG Life Sciences Inc. due to its micro-cap status and trading on the OTC market. Key valuation metrics such as price targets and ratings are not available. Investors should conduct their own thorough research and consider the company's high-risk profile, early-stage development, and limited financial resources. Growth considerations include the potential for successful clinical trials and strategic partnerships.
What are the main risks for VGLS?
The main risks for VG Life Sciences Inc. include its limited financial resources, small team size, and early-stage development of therapies. The company faces significant competition from larger pharmaceutical and biotechnology companies. Regulatory hurdles and lengthy approval processes pose additional challenges. Failure to secure funding for research and development or unsuccessful clinical trial outcomes could significantly impact the company's prospects.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and management team.
- OTC market carries higher risk compared to major exchanges.
- Analyst coverage is not available for this stock.